相关实验视频

Updated: Jul 4, 2025

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

区分病理和生理纤维解:不像传统的血栓造影一样简单

Hunter B Moore¹, Christopher D Barrett², Ernest E Moore³

¹From the Department of Surgery, Transplant Institution, AdventHealth at Porter Hospital, Denver, CO (HB Moore).

Journal of the American College of Surgeons

|February 1, 2024

概括

结合快速血小板造影 (rTEG) 和组织等离子体激活剂TEG (tPA-TEG),可以改善创伤患者的死亡率预测. 这种增强的纤维素分析分析有助于分层风险,并指导患者特定的治疗策略,以获得更好的结果.

科学领域:

创伤血液静止和凝血.
血栓形成显微镜应用血栓形成显微镜应用
纤维解析表型化纤维解析表型化

背景情况:

传统的快速血栓形成显微镜 (rTEG) 无法区分纤维解质关闭和缺纤维解质,因为纤维解质活性相似较低.
组织等离子素激活剂 (tPA) TEG可以识别枯竭的纤维解质抑制剂,从而有可能在创伤后区分所有三种病理纤维解质表型.
结合rTEG和tPA-TEG可能可以更精确地分层纤维分解表型和相关的死亡风险.

研究的目的:

评估rTEG和tPA-TEG在区分创伤后纤维素分解表型方面的联合功效.
评估这些综合分析对创伤患者死亡风险分层的预测价值.
为了确定组合rTEG和tPA-TEG是否比单个测试提供更好的死亡率预测.

主要方法:

包括981名成年创伤患者,在受伤后2小时内进行RTEG和tPA-TEG.
在最大振幅 (LY30) 后 30 分钟使用 rTEG 溶解定义的初始纤维分解表型.
利用tPA-TEG LY30上的Youden指数来定义tPA敏感 (抑制剂耗尽) 和tPA耐药的表型,创建9个不同的组来评估死亡风险.

主要成果:

在rTEG和tPA-TEG的组合中,发现了9种纤维解质表型中的5种与死亡率增加相关.
>35.5% (敏感) 和<0.3% (耐药) 的tPA-TEG LY30值与死亡率的增加显著相关 (分别为OR 9.2和6.3).
综合分析 (AUC 0.80) 在预测死亡率方面显著超过单独的RTEG (AUC 0.63) 和tPA-TEG (AUC 0.75),允许将其凝结为3个关键的病理表型.

结论:

结合RTEG和tPA-TEG可显著提高创伤患者死亡率的预测.
这种综合方法可以更好地区分复杂的纤维素分解表型,包括真正的超纤维素分解,早期纤维素分解关闭和低纤维素分解.
由rTEG和tPA-TEG分析结合而成的患者特定策略有可能改善创伤患者的治疗结果.

更多相关视频

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

相关概念视频

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...